ChiCTR2200055201 版本V1.5 版本创建时间2023/01/15 23:35:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200055201 

最近更新日期:

Date of Last Refreshed on:

2022-07-23 17:16:36 

注册时间:

Date of Registration:

2022-01-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

CT引导圆孔射频热凝治疗原发性三叉神经痛扫描层厚的选择

Public title:

Selection of scanning slice thickness for primary trigeminal neuralgia with CT-guided round hole radiofrequency thermocoagulation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

关于CT引导经圆孔射频热凝治疗三叉神经痛技术细节的描述

Scientific title:

Description of the technical details of CT-guided transforaminal radiofrequency thermocoagulation for trigeminal neuralgia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩紫芯 

研究负责人:

倪华栋 

Applicant:

Han Zixin 

Study leader:

Ni Huadong 

申请注册联系人电话:

Applicant telephone:

+86 18361268132

研究负责人电话:

Study leader's
telephone:

+86 15068386387

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hanzixin1997@163.com

研究负责人电子邮件:

Study leader's E-mail:

huadongni@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

研究负责人通讯地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

Applicant address:

1882 Zhonghuan Road South, Chengnan Street, Nanhu District, Jiaxing, Zhejiang

Study leader's address:

1882 Zhonghuan Road South, Chengnan Street, Nanhu District, Jiaxing, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

The First Hospital of Jiaxing

研究负责人所在单位:

嘉兴市第一医院

Affiliation of the Leader:

The First Hospital of Jiaxing

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LS2021-KY-414

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴市第一医院医学伦理委员会

Name of the ethic committee:

The First Hospital of Jiaxing Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-07 00:00:00

伦理委员会联系人:

钱建萍

Contact Name of the ethic committee:

Qian Jianping

伦理委员会联系地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

Contact Address of the ethic committee:

1882 Zhonghuan Road South, Chengnan Street, Nanhu District, Jiaxing, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

The First Hospital of Jiaxing

研究实施负责(组长)单位地址:

浙江省嘉兴市南湖区城南街道中环南路1882号

Primary sponsor's address:

1882 Zhonghuan Road South, Chengnan Street, Nanhu District, Jiaxing, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院

具体地址:

南湖区城南街道中环南路1882号

Institution
hospital:

The First Hospital of Jiaxing

Address:

1882 Zhonghuan Road South, Chengnan Street, Nanhu District

经费或物资来源:

嘉兴市第一医院

Source(s) of funding:

The First Hospital of Jiaxing

研究疾病:

三叉神经痛  

Target disease:

trigeminal neuralgia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索不同CT扫描层厚,对引导圆孔射频热凝治疗原发性三叉神经痛的影响。  

Objectives of Study:

To explore the effect of different CT scan slice thicknesses on guided round hole radiofrequency thermocoagulation in the treatment of primary trigeminal neuralgia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄>18岁;
2.根据ICHD-3诊断符合V2三叉神经痛或合并V1/V3三叉神经痛的患者;
3.术前NRS评分≥6;
4.病程>1个月;
5.单独或联合应用卡马西平、加巴喷丁、普瑞巴林治疗后疼痛仍未缓解或不能耐受不良反应者。

Inclusion criteria

1. Aged > 18 years;
2. Patients diagnosed with V2 trigeminal neuralgia or combined with V1/V3 trigeminal neuralgia according to ICHD-3;
3. Preoperative NRS score >=6;
4. Course of disease > 1 month;
5. Patients with unrelieved pain or intolerable adverse reactions after carbamazepine, gabapentin and pregabalin treatment alone or in combination.

排除标准:

1.拒绝微创治疗及参与研究者;
2.继发性三叉神经痛,例如由占位性病变或多发性硬化症引起的三叉神经痛;
3.穿刺部位局部感染;
4.精神疾病或智能障碍;
5.严重肝、肾、心、肺疾病;⑥术前有凝血功能障碍或对局麻药过敏。

Exclusion criteria:

1. Refuse minimally invasive treatment and participate in researchers;
2. Secondary trigeminal neuralgia, such as trigeminal neuralgia caused by space-occupying lesions or multiple sclerosis;
3. Local infection at the puncture site;
4. Mental illness or intellectual disability;
5. Severe liver, kidney, heart and lung diseases; 6. Coagulation dysfunction or allergy to local anesthetics before surgery.

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2023-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-03 00:00:00 To 2023-01-01 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

20

Group:

Group A

Sample size:

干预措施:

CT层厚=1mm

干预措施代码:

Intervention:

CT scanning layer thickness=1mm

Intervention code:

组别:

B组

样本量:

20

Group:

Group B

Sample size:

干预措施:

CT层厚=2mm

干预措施代码:

Intervention:

CT scanning layer thickness=2mm

Intervention code:

组别:

C组

样本量:

20

Group:

Group C

Sample size:

干预措施:

CT层厚=3mm

干预措施代码:

Intervention:

CT scanning layer thickness=3mm

Intervention code:

组别:

D组

样本量:

20

Group:

Group D

Sample size:

干预措施:

CT层厚=5mm

干预措施代码:

Intervention:

CT scanning layer thickness=5mm

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

嘉兴 

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Jiaxing University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

调针次数

指标类型:

主要指标

Outcome:

Needle adjustment times

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术完成时间

指标类型:

主要指标

Outcome:

Operation duration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

辐射量

指标类型:

主要指标

Outcome:

Ray quantity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻木程度

指标类型:

次要指标

Outcome:

Numbness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血肿

指标类型:

次要指标

Outcome:

Hematoma

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

有效率

指标类型:

次要指标

Outcome:

Response rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

复发率

指标类型:

次要指标

Outcome:

Recurrent rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Null

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用完全随机化方法,用stata软件生成随机数字表,由数据分析者完成。

Randomization Procedure (please state who generates the random number sequence and by what method):

The complete randomization method was adopted, and the random number table was generated by Stata and completed by the data analyst.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国知网,http://www.cnki.net/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.cnki.net/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

海泰电子病例系统3.0,EXCEL统一记录上传

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data are collected by Heitai Electronic Medical Record System 3.0,then use EXCEL to record data and upload.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-01-02 21:20:59